Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...
The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...
AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral...
Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its IL-23p19 antibody Omvoh (mirikizumab) for expanded use in Crohn’s disease...
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.
This cautious stance follows a series of setbacks for AbbVie, including last month’s failure of two mid-stage trials for a schizophrenia drug.
This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made...
Monday, December 9, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and...
/Abbvie%20Inc%20billboard%20-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
AbbVie has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.
Pfizer’s PFE stock has declined 7.8% in the past month. Though the stock has been affected by declining sales of its COVID products, a lot of this stock price decline could be due to the broader drug/biotech...